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ABSTRACT
Tendon injury can occur from activity-induced overuse, complete laceration or
aging-related degeneration and these injuries commonly fail to wound heal without
clinical treatment. Moreover, activity-induced overuse accounts for approximately half of
all sports injuries and has highest occurrence rates in athletes playing football, baseball
and basketball. Current non invasive technique to rest and ice the damaged tissue in
combination with either oral NSAIDS or corticosteroid injections has shown little
promise with only ~60% of cases regaining functionality of the tendon (Paterno et al.,
2013).
From the literature, this seems to be caused by a combination of poorly perfused tissue
along with a lack of cellular control throughout the inflammatory and remodeling phases
of wound healing. Because of this, new generations of experimental therapies involve
implementing a cocktail of growth factors and cytokines in an effort to control and
perhaps expedite the wound healing process. In order for this approach to become
clinically effective, improvements must be made in our understanding of TIMP-MMPCOL interaction as well as chemokine-induced differentiation of involved macrophages
(Morita et al., 2017; Martinez et al., 2014). This thesis considers the differential gene
expressions between healthy and diseased tendons for further insight into tendon
pathophysiology and possible improvements in therapeutic approach.
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CHAPTER ONE
INTRODUCTION AND RESEARCH AIMS
1.1 Motivation
The long-term goal of this thesis is to improve my understanding of the
underlying molecular and cellular mechanisms, which lead to tendinopathy. In order to
accomplish this, I took a systems biology perspective observing significant differential
gene expressions between healthy and disease state from previously published microarray
data on NCBI. This in combination with a review of the literature gave a more robust
theory about why tendons often fail to properly wound heal. Original methods of this
research design followed PCA in attempt to tag differentially significant gene expression
levels to a specific disease state. Upon approaching this topic I found many areas within
the original methods of microarray data collection and microarray normalization that
raise concerns about the significance of statistics applied to the array data.
In order to implement statistical methods for preliminary results without designspecific concerns of microarray collection and normalization the Bioconductor package
in R was used with functions previously created for use on microarray data. Because of
this lack of significance, statistical observations of interest were based on what has been
previously seen in the literature and findings from log-fold change expression analysis.
Current work shows issues in the inflammatory signaling pathways of both tenocytes and
macrophages as well as control of extracellular matrix anabolism and catabolism (Scott et
al., 2011; Morita et al., 2017). Because of this, methods were refined for observation of
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significant changes in chemokines of the interleukin family, matrix metalloproteinases,
tissue inhibitor of metalloproteinases and collagen production.
My future career goals are to improve my understanding of biomolecular
engineering, cellular/molecular biology and computational modeling in order to approach
complex problems such as this one with a combination of finite element modeling (FEM)
and bioinformatics. As I approach PhD candidacy in BDSI I will hold close to improving
my understanding of this topic and further refined statistical methods. I am also hopeful
to find the opportunity to apply the tools that I have gained from this research towards a
dissertation surrounding the topic of cancer physiology.
1.2 Research Aims
In this study we observe significant changes in gene expression between healthy
and diseased tendons through differential expression with sample weighting and principal
component analysis. We will look for evidence supporting what has been previously
shown in literature with respect to expressions of matrix metalloproteinases, tissue
inhibitor of metalloproteinases and collagen types. Future iterations of this study should
consider GSEA in order to represent a more defined separation between healthy and
diseased states as well implementation of these statistics on mRNAseq data pertaining to
the topic instead of microarray.
1.3 Significance
Activity-induced overuse accounts for approximately half of all reported sports
injuries and current treatments have proven to be relatively ineffective. Non invasive
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technique to rest and ice the damaged tissue in combination with either oral NSAIDS or
corticosteroid injections has shown little promise with only ~60% of cases regaining
functionality of the tendon. There is a need for novel therapies able to control the cellular
and molecular mechanisms at hand in tendon pathology. However, this is a relatively new
approach that will require a more robust understanding of cellular signaling than
previously stated in the literature in order to be a safe and effective therapeutic.
The three grand challenges of engineering most accurately applied to my research
goals are to engineer better medicines, advance health informatics and engineer tools for
further scientific discovery. As medicine continues to become more personalized and
focused on molecular causation and drug targeting, computational tools including
informatics and FEMs are becoming more and more a necessity to take observations on
complex biological problems with a large amount of inputs. Engineering safer and more
effective therapeutics plays a major role in bioengineering and is often the framework of
interesting biological questions. With respect to this thesis as well as a large amount of
informatics work, statistical proof of molecular interactions often leads to new
understandings of pathophysiology.
This informatics perspective in combination with review of the literature may also
lay the groundwork for an FEM in attempt to observe changes in tendon physiology over
time with respect to genes of interest as inputs. This continued reiteration of modeling
and collecting statistics is key to expediting the translation of biomedical bench top work
into clinical applications.
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CHAPTER TWO
LITERATURE REVIEW
2.1 Introduction
Tendons are composed of connective tissue and function as mechanical
connections between musculature and bones surrounding a specific joint, acting as levers
for locomotion. Tendons have also been noted to have high tensile strength and minimal
plastic deformation in order to transmit heavy loads. These mechanical properties present
a structure to function relationship as seen in Figure 2.1 with triple helices of
tropocollagen fibers compacted into fibrils along a single axis.
Each step of this hierarchy from fibril to fascicle tissue level has a thin layer of
reticular cartilage called the endotenon, which allows for subunits to move independently
without frictional damage. At the tendon level this reticular cartilage is defined separately
as endotenon (inner) and epitenon (outer). Finally, some tendons have a true synovial
sheath encasing the epitenon with a thin layer of synovial fluid in between called the
paratenon. This functions as protection from friction on a larger scale and is seen most
commonly in high-stress tendons where loading can be significantly greater than total
body weight such as the achilles and peroneal tendons of the ankle.
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Figure 2.1: Tendon Structure: Collagen Type 1 ECM

Tropocollagen is a ~300nm long triple-helix protein which is made
thermodynamically favorable via its high amount of hydroxyproline and proline
residues. Hodge and Petruska concluded from transmission electron microscopy (TEM)
that tropocollagen has a one-fourth staggered arrangement when formed into fibrils. This
means that for every five proteins aligned laterally in the overlap region, there are four
molecules lateral to the gap as seen in Figure 2.2. These intermittent extra spaces are
filled by proteoglycans and glycosaminoglycans (GAGs) whose function is thought to aid
in the protection of tenocytes from compressive forces (Parvizi et al., 2010).

9

Figure 2.2: Tropocollagen Arrangement within a Fibril (Parvizi et al., 2010)
Known as a dense regular connective tissue, the majority of a tendons
composition is water weight, with collagen type 1 making up 85% of it’s dry weight;
collagen type 3 makes up 5% and proteoglycans make up about 0-5% of total dry weight.
They maintain a small cell population of tenocytes defined as spindle like fibroblastic
cells running along the axis of loading and responsible for collagen production as well as
initial cellular response to injury (Orthobullet, 2016). It has been noted in the literature
that under pathologic condition tenocytes shift from a “spindle-like” morphology into
rounded cells. Furthermore, the healthy morphology aids in cell-to-cell communication
and mechanotransduction. These finger-like extensions surround and attach to bundles of
collagen via membrane bound integrin receptors in order to produce a continuous cellular
response to cyclic-loading. Secondly, these extensions also form gap junctions from cell
to cell allowing for a synergic response to changes in local physiology (Parvizi et al.,
2010).
This poses an interesting question about the origin of tendinopathy. Causation via
disoriented ECM has been previously accepted as the initial cause of disease, but it may
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be more plausible that disease state is caused by disordered and poorly anchored
tenocytes attempting to regain connection to collagen ECM and other cells perpendicular
to the axis of loading (Smith et al., 2010). Although it will not be discussed very heavily
in this thesis, it should be noted that cyclic-loading in a rehabilitative manner plays a vital
role in proper tendon healing and further research must be done in order to improve the
timing of clinical methods towards more improved response by tenocytes.
Tendon pathology can occur from overuse, laceration or age related degeneration,
but the underlying issues in regenerating healthy tendon from all three of these
pathologies are similarly marked by poor perfusion, a lack of cellular response and weak
control over the timing of inflammatory and remodeling processes (Paterno et al., 2013).

2.2 Tendon Biomechanics
Tendons are considered a mechano-adaptive tissue type meaning that they are
capable of altering their structure and cellular functioning based on mechanical inputs
from its surrounding environment. It has been shown that physical activity can have
anabolic effects similar to that of micro tearing in musculature wherein tendon diameter
increases via new ECM production. This gives tendons the increased tensile strength
needed in order to continue undergoing high intensity exercises. However, at some
threshold of microscopic failure the tendon becomes pathologic and can no longer correct
damages to its ECM efficiently. This is marked by disorganized matrix, reduced
mechanical properties, and proliferation of disease state tenocytes (Wang et al., 2012).
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Figure 2.3: Tendon Stress-Strain Curve (Wang et al, 2012)
Figure 2.3 above shows a general tendon stress-strain curve with the
‘physiological range’ being regular activity induced strain at a maximum of around 4%.
The linear region defines the point when the collagenous ECM is uncrimped and
withstands over 4% lengthening before causing microscopic failures. Strains above 8%
will likely cause macroscopic rupture (Wang et al., 2012). It is also important to note that
tendons have been shown to have viscoelastic properties meaning that it responds to
strain with both elastic and plastic deformation based on rate of the force applied. The
elastic deformation can be seen above within the argument of ‘crimped’ collagen
structure stretching as an initial response to strain. Creep strain occurs when the tendon is
held at a constant stress and plastic deformation continues to occur causing an increase in
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strain. This leaves the tendon with slightly weaker mechanical properties after heavy use
from physical activity and if not rested properly will lead to overuse injury.

2.3 Injury and Repair

Figure 2.4: Time Scale of General Wound Healing Process (William et al., 2008)
Natural wound healing occurs in 3 major steps; Inflammation or hemostasis,
proliferation and remodeling. Inflammation is the body's immediate response to injury,
which is initialized by platelets plugging the damaged area to avoid continued blood loss.
During this phase M1 phagocytic macrophages are recruited to the damaged site in order
to begin clearing debris whether it be infectious material, dead cells or disorganized
ECM. Fibroblastic cells producing new ECM is a common characteristic of the
proliferation phase of wound healing, but in tendons this ECM is often in high amounts
of collagen type 3 instead of type 1. The fibroblastic cells producing new ECM are a mix
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of tissue resident tenocytes as well as activated M2 macrophages. In the final stage of
wound healing disorganized collagen type 3 is broken down and remodeled into
organized ECM with an increase in collagen type 1 composition as seen in healthy tissue
(Lin et al., 2004; Martinez et al., 2014).
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Chapter Three
Literature Review: Microarray, Normalization and PCA

3.1 Biomedical Constraints
While the work done by Jelinsky and others has aided our understanding of
tendinopathy and its fibrosis-like pathologic characteristics, there are still many areas of
biological diversity that have not been previously considered in the investigation of
tendon microenvironments. Firstly, the most obvious biological constraints are
differences in sex and age. The Jelinsky study was majority male (65%) and 83% of
patients were above the age of 45 with a maximum age of 66. There was one 32 year-old
male that was included in the study with a 10 year age difference between he and the rest
of the cohort. In terms of model bias, this tells us that the expression results are somewhat
skewed toward a male population with age-related degeneration. While these are obvious
differences within the cohort, they are not likely to be the major factors of variation
within the gene expression results.
Seemingly more interesting, is the variation amongst anatomic location of tissue
collection and past history of corticosteroid injections. The majority of the cohort had
rotator cuff damage accounting for 70% of cases. Beyond this the study included two
extensor carpi radialis brevis (ECRB) tears, two flexor tendon tears, two patellar tendon
tears and one distal bicep tear. This may be a more major factor in the causation of
variation in results, because these tendons have cell populations that are inherently
different due to their location and function. It may be more sensible to consider
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expression analysis for only RTC tears and reduce cohort size from 23 to 16. ECRB tears
as well as the distal bicep tear are more likely to have negligible variation in comparison
with RTC tears due to similar anatomic location and loading, but patellar and flexor
tendon pathologies seem to be unintuitive inclusions. As described in chapter 2, flexor
tendons have considerably different anatomy with specialized flexor sheaths in order to
allow for small precise movements at high frequency without damage. Patellar tendon
inclusion seems most surprising because of the load and frequency of impact encountered
by lower limb tendons. These loads are significantly greater then RTC and ECRB
tendons in the upper limb. All of these anatomic differences will lead to differing cell
response and therefore different expressions across samples within analysis. Note that
this affects both diseased and healthy tendon samples. Healthy sample selection differed
amongst studies based on feasibility of access while biopsy was being performed at the
disease site. For most RTC cases a healthy sample was collected from another
subscapular tissue region or from healthy bicep tissue. Patellar tendon tear’s healthy
counterparts were collected from the quadriceps and flexor tendon counterparts were
collected from healthy tissues distal to the injury site. Further study that may be of
interest could be a comparison of healthy and disease tissues with respect to their
anatomical locations and then considering differences in expression across anatomical
location. This may give further insight into specific tissue pathologies as well as an
understanding of mechanical loading’s effect on expression and disease progression.
Lastly the consideration of corticosteroid injections and their effects on cellular
expression may be the most important area of biological variance within this study. The
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study collected the number of steroid injections per patient. It’s a plausible assumption
that this was collected for retrospective review, as it was not contained in the results or
heavily within the discussion. Number of injections ranged from 1 to 3 and only 52% of
the cohort received steroid injection. Further study in comparing steroid and non-steroid
injection cohorts may give insight on how they change cellular expression and more
interestingly the long term effects of corticosteroids on tendon pathology. The majority of
works done in considering the efficacy of corticosteroids on mesenchymal cell lines only
consider tissue health for one to three months after injection. There have also recently
been retrospective studies on human corticosteroid injections due to the fact that patients
return with complaints of returned pain. This tells us that the steroids are not a feasible
long-term solution and that the pain returns with further damaged tissue. One of the most
referenced alternatives to corticosteroids is autologous platelet rich plasma injections,
which have been shown to improve pain intensity as well as physiological function longterm. However, platelet rich plasma is not clinically available and corticosteroids have
been shown to be more effective in immediate pain mitigation (Tang et al., 2019).
Unfortunately, there was also no collection on the timing of the corticosteroid injections;
how long prior to biopsy the injections were received or how far apart the injections were
administered for those who received multiple injections. This would have been vital
information for further studies considering the long-term efficacy of steroid injections.
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3.2 Affymetrix Microarray
Microarray is a laboratory tool that has allowed for the first generation of
genomic-based research of disease. This has been made possible by microarray’s
capabilities of collection and analysis on very large sets of data and is accomplished
through hybridization of genomic fragments onto an array of oligonucleotide
probes. Microarray allows us to collect an initial genome library for a specific species
and then study changes in cell populations within the species; most notably ‘The Human
Genome Project’. In order to collect differential gene expression, mRNA is extracted
from both test and control group and labeled separately with fluorescent dye as seen
below in Figure 6 (Karakach et al., 2010). Methods in choosing probe type have varied
since the origin of microarray based on differing theories of genetic precision and
improved statistical value; discussed here are methods of Affymetrix GeneChip
microarray as it pertains to the data used in this thesis.

Figure 3.1: Microarray methods with Cy3 and Cy5 dyes marking control state and target
expressions (Karakach et al., 2010)
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Affymetrix uses the method of “probe sets” composed of 9 to 16 rather short
probes (25 nucleotides in length) in order to account for non-specific binding and give a
relative measure of noise present. Non-specific binding occurs when a ligand binds to
something other than its target due to stochastic environment, collision theory and
relatively strong mismatched affinity. This is often seen to cause noise in microarray.
Affymetrix attempted to tackle this problem by placing both perfect match (PM) and
mismatch (MM) probes within each probeset. This means that (PM) probes are composed
of a 25 nucleotide transcripts targeting a gene of interest while the (MM) counterpart is
an identical transcript with the exception of a single base replacement in the middle
position (Karakach et al., 2010). Perfect match probes on these arrays were made bias to
the 3’ end of their respective target genes in an attempt to avoid mRNA degradation bias
and improve the unique characteristic of each probe for improved target precision (Penn
State Stat 555, 2018).
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Figure 3.2: Perfect Match (PM) Mismatch (MM) design for Affymetrix
GeneChip (Penn State Stat 555, 2018)
Unfortunately this attempt has been shown to be crowded with issues. This 3’ bias
has been shown to instead cause weak probe hybridization and missing expressions from
splice variants. Alternative splicing is a post-transcriptional regulating mechanism in
which cells control which sections of an mRNA transcript will be processed through the
translation step into a protein. Enzymes within the nucleus, which generally remove
introns and leave exons intact, can alternatively choose to remove entire proteins from its
code prior to sending the mRNA for translation. Therefore, Affymetrix 3’ bias fails to
capture a certain portion of splice variants. Additionally, the MM probes have been
unsuccessful in accounting for background and have been removed from new generations
of microarray (Penn State Stat 555, 2018).
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3.3 Normalization
Normalization is an important biomedical research technique applied to data in
order to remove unwanted noise that has been produced externally from the biological
question at hand. A simple example applied to microarray; if data collection was done at
separate time points, it is possible that all of the intensity values for one array will
slightly be greater or less than all values of another. This is caused by changes in the
intensity of the light bulb used in activating the luminescent mRNA. The most common
way to account for these issues is called quantile normalization.
Quantile normalization ranks all intensity values from each sample separately
from one another and then takes a mean value across all samples for each ranked
position, greatest to least. Now these mean values replace the originally ‘uneven’ values
across each ranked set and rankings are indexed back to their specific gene expressions as
seen in Figure 3.3.

Figure 3.3: A simple illustration of Quantile Normalization
(Starmer, StatQuest 2017)
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While this has been shown to produce low variance and low bias with simplicity
of its mathematical computing, it has also been found that quantile normalization can
impact the biological differences within data raising questions about its effectiveness
(Boes, 2005).
Returning to the discussion of (PM) and (MM) probes defining a probeset on
Affymetrix arrays; although it has been shown to be inefficient compared to other array
and mRNAseq techniques, these microarrays are still used for comparison to new data
which requires probeset summarization as background correction beforehand. The initial
model for probeset summary was an average difference between the PM and MM probes
within a set such that PM - MM . As discussed earlier, this method was found to be
ij

ij

unsuccessful and it has been noted to have multiplicative errors in intensity values,
unaccounted for background variation and most concerning, greater intensity values from
MM probes than PM probes.
There have been many attempts in the literature to improve upon these issues in
order to make this type of GeneChip array data viable. But, because there are so many
normalization steps to be considered, transforming steps on data specific to Affymetrix
GeneChips have been programmed within the R Bioconductor package in an attempt to
standardized methods and report results back to literature for further improvement.
3.4 Further Data Transformations and Bioconductor
From normalization methods and microarray techniques discussed thus far, it is
clear that there are many steps in which error may occur. Bioconductor is an ongoing
NCBI project aimed toward expediting data transformations accounting for these errors
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with standardized methods as well as providing plotting methods shown to be effective in
previous work. Bioconductor uses the Gene Expression Omnibus as a compatible genetic
expression repository allowing for genetic data analysis to be open to the scientific
community. This standardization allows for more reproducible microarray results and the
package has many different transformations based on differing types of microarray. After
further study of the Affymetrix HGU133plus2 platform and Jelinsky’s methods, the
original dataset was renormalized and further analyses were considered. Firstly, quantile
normalization may not be the most sensible normalization technique. It is often used
during RNAseq preprocessing. It may also apply to some microarray data based on the
platform used, but for Affymetrix PM-MM probesets it has shown to be unintuitive.
Jelinsky methods followed a previous paper observing the same biological phenomena a
rat model. These methods were as follows; firstly the probsets from each sample were
lowess (locally weighted scatterplot smoothening) normalized using a Bioconductor
variation called MAS 5.0 in order to account for spot intensity variations. Jelinsky
included a ‘soft’ set of MAS 5.0 lowess normalized sets in the GEO database as well as
the raw cdf (raw intensity values) files. Under consideration of simplicity and
reproducibility, these soft files were used in later iterations of analysis. However, these
GSEs still need to be transformed from normalized intensity values in order to
graphically consider fold change. In order accomplish this, the set was separated into
healthy (control) and disease state and mean intensity values were log2 transformed for
input into a volcano plot. This visualization method allows for consideration of
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significantly up regulated genes in combination with their significance with p-values
calculated via a simple t-test across the control and disease sets.
3.5 Principal Component Analysis
Principal component analysis (PCA) is a statistical method aimed toward
capturing connections across an n-dimensional dataset and presenting them in a kdimensional subspace (where k <=n) for observation with a known percentage of
variation captured. For simplicity, consider that there are only two genes of interest with
sample counts that can be plotted on an x-y plane. Note that if there were more than three
genes, we would not be able to graphically represent the problem due to dimensionality
issues. Because of this, PCA aims to condense all of the data into fewer dimensions
called principal components without changing sample counts magnitude relative to each
other. It is most commonly reduced to two dimensions for easy observation, but many
instances require more principal components in order to minimize the loss of data
variation across samples.
PCA accomplishes this by shifting the data such that its centroid is bound to the
origin and then defines a line of best fit based on maximizing the sum of squared
distances from each counts projection on the line to the origin. This finds the optimal fit
for the data because the distance from the origin to the projection of each point is the
inverse of the distance from each point to its projection on the line. This is depicted in
Figure 3.4 where distance ‘a’ remains constant requiring lines ‘b’ and ‘c’ to be
uncorrelated due to geometrical constraint. PCA uses this sum of squares method because
it is the easier method to calculate. Even though minimizing distant ‘b’ may seem
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intuitively correct the two approaches are equivalent. This line now defines principal
component one, and its slope with respect to the original axes comparing two genes
defines its covariance within the data.

Figure 3.4: Illustrative Aid for Principal Component Analysis; (a) top left: initial
sample scores, (b) top right: shifted scores with initial line defined, (c) bottom
left: line approaching optimal fit by sum of squares and (d) bottom right:
conceptualization of the inverse relationship between distances a and b within
PCA methods. (Starmer, StatQuest 2018)
The sum of squared distances from data projections onto any principal component
is defined as that components eigenvalue. A principal components covariance for a two
gene model describes the weighting that each gene had on the orientation of the
component, thus giving insight to which gene may be causing differences in sample
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clusters. Covariance is defined mathematically by each PC’s eigenvalue divided by the
number of samples minus 1. An eigenvector is simply a unit vector bound to the origin
and in the direction of any principal component, calculated by dividing both of its x and y
projections on the original plane by its distance from the origin. The proportion of each
gene contained in the eigenvectors projections are called loading scores. PC2 is simply a
line perpendicular to PC1 and bound to the origin. Therefore, the eigenvector defining
PC2 will be the inverse of PC1.
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Chapter Four
Methods in R, and Discussion of Results
4.1 Methods
A literature review was conducted to determine clinically relevant gene
expressions within tendinopathy. From review, MMPs, TIMPS, chemokines related to
inflammatory signaling, and collagen-producing genes were found to be the most
relevant. Datasets were collected from the GEO database containing 46 microarray
samples from 23 human patients (23 healthy site biopsies, 23 diseased site; 3 mm2 cuts).
A two-tailed t-test was performed to compare the largest fold-change expressions from
healthy to diseased states. A Principle Component Analysis was then performed. The
goal of PCA is to show relationships between the scores of variable data and loadings of
sample sets. In this regard, it should show specific genes and their likelihood of
expression in a healthy and diseased tendon. The two-tailed t-test was performed on the
relative expression set normalized by the original author, while normalization for PCA
was done separately in R. From the previous study, each probe set was normalized to a
mean signal intensity value of 100. The David Bioinformatics Database was used for
conversions from probe ID to gene ID where necessary.
To complete PCA, the raw sample sets were first quantile normalized by finding
the ranked per-row mean across all samples and saved into ‘micro_mean’. These
ranked-mean values were then indexed back into the original ‘micro’ dataset using
micro$Gene_id. Probes with missing expression values were at this point removed across
all samples and the new data frame saved into ‘df_final’ (lost 382 probes). Data was
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collected for PCA variance ratios as well as scores and loadings along each principal
component. Log2 fold-change normalization was later considered and observations were
taken from Figure 4.3 and Table 4.3 below.
4.2 Results
From the literature, the genes found to have significant-fold change include
ADAM12, POSTN, IL13RA2, IL-Beta, IL-6 and TNF-alpha. From differential
expression, COL4A3 (p<0.05) was significantly down regulated in tendinopathy. This
and other significant genes regulations are shown in the tables below with respective
sample weighting shown. From PCA in R, covariance across PC1 and PC2 was
unfortunately low at [5.33%, 4.26%] respectively. There was notable score clustering
along principal component two. These probes were converted and can be seen in Table
4.2. Interestingly, the renormalized volcano plot showed up regulation of genes involved
in cellular motility, division and differentiation as well as IL11, which have been
previously studied with respect to the fibrosis pathway. However, the more concerning
result was the down regulation of a plethora of muscular probes such as troponin, myosin,
and titin transcripts.
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Table 4.1: Genes of significant differential expression, log fold change and weighting by
sample Note: In table 2, GSM639748-GSM639770 (left) are healthy samples and
GSM639771-GSM630793 (right) are disease samples.
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Figure 4.1: Sample Loadings across PC1 and PC2 in R
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Figure 4.2: Gene Scores Across PC1 and PC2 in R

Table 4.2: Genes clustered along PC2 - 207733_x_at and 204927_at show high
variable score, 204903_x_at and 213820_s_at show low score.
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Figure 4.3: Volcano Plot of log2 fold-change probe values with adjusted p-values
(Diseased up-regulation in the positive X direction).
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Log2(Fold Change)

Raw p-value Probe Names

-6.55325 0.02999314 222287_at
-6.183617 0.02739283 203861_s_at
-5.555775 0.03837896 206844_at
-5.253121 0.02821672 219772_s_at
-5.212994 0.02968449 204810_s_at
-5.152808

0.0215428 204865_at

-5.152344 0.03471813 205177_at
-5.144982 0.03291095 223572_at
-5.07893 0.02735041 208084_at
-4.858404 0.02473192 222954_at
-4.85198 0.02600108 203863_at
-4.706768 0.02394919 208083_s_at
-4.615081 0.02695138 206768_at
-4.412438 0.02125188 228406_at
-4.347735

0.0322874 226228_at

-4.319374 0.03313139 205163_at
-4.314426 0.02129247 235367_at
-4.203811 0.02251591 213201_s_at
-4.173112 0.02858036 203862_s_at
-4.159186 0.02144479 235261_at
-4.146987 0.02354185 242729_at
-4.130526 0.01164791 1553301_a_at
-4.112497 0.02733729 242679_at

Table 4.3: Significantly down-regulated probes: disease vs. control.
Green = expressions related to muscle tissue-type (myosin, titin, and troponin transcripts)
Yellow = actin alpha 2 transcripts
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4.3 Discussion of Initial Normalization and PCA
Due to such a low variance, results from PCA were not significant and used only
to further consider what has been seen in the literature. Interestingly, three of the four
probes identified have been shown to be involved in differentiation, remodeling and cell
proliferation. As seen in Figure 4.2, clusters of healthy and diseased sample loadings
along PC2 defined disease states.
First we will discuss genes related to the healthy state cluster, followed by genes
associated with the diseased cluster. RASSF7 is a Ras family associated protein, which
has been studied most heavily on its regulations of actin cytoskeleton. It has been shown
to play a role in negative regulation of apoptosis via JNK activation. Interestingly, JNK
has been shown to be an apoptosis regulator based on stress-inducing stimuli as a part of
the mitogen-activated protein kinase (MAPK) family. These stimuli include
inflammation, oxidative stress, osmotic stress and cytoskeletal changes (Zeke et al.,
2016). The protein encoded by PSG9 belongs to the immunoglobulin superfamily. It has
been studied most extensively in fetal development for cellular adhesion and is thought to
inhibit platelet-fibrinogen interactions, and important pathway involved in inflammatory
response (NCBI, PSG9).
The two genes associated with the diseased cluster were ATG4B and STARD5.
ATG4B is involved in the autophagy process in which damaged organelles and proteins
are destroyed within a cell. It is considered to be a cellular homeostatic mechanism
necessary for differentiation and non-apoptotic cell death, but studies of this gene are still
in very early stages and mostly focus on its prevalence in colorectal cancers (NCBI,
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ATG4B). Lastly, STARD5 seems to be involved in intracellular transport of sterols and
other lipids to the endoplasmic reticulum, but involvement in tendinopathy or it’s
underlying pathways has not been seen in the literature.
From review of the literature, the majority of significant differentially expressed
genes involved in tendinopathy are cytokine-producing and matrix remodeling
genes. Cytokine-producing genes IL-1beta, IL-6 and TNF-alpha have been extensively
studied for this application and from systematic review it has been shown that IL-6 is upregulated in damaged tendons as well as healthy tendons after exercise, while TNF-alpha
and IL-1beta showed little significant fold change (Jelinsky et al., 2011).
From the original differential expressions, IL-13RA2 was also found to have a
statistically significant fold change greater than five. IL-13RA2 produces specific protein
units of the IL-13 receptor complex, which regulates the release and uptake of IL-13.
Interestingly, IL-13 has been shown to promote macrophage differentiation into phase
two phagocytic cells. In macrophages, the M2 phase of differentiation is a period in
which the cell becomes active in producing new extracellular matrix and is an integral
state of wound healing. IL-6 acts in a very similar manner, but IL-6 has been shown to be
secreted by macrophages and recruit B-cells with pattern recognition for pathogenic
debris.
IL-1beta is the final inflammatory factor under consideration, and it was found to
have no significant fold change in tendinopathy. This seems inconsistent when
considering the normal pathway of cytokine up-regulation during an inflammatory
response, but could be legitimized by the assumption of a ‘lack of inflammatory
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response’ in tendinopathy. This makes sense because IL-1beta is expressed by activated
macrophages and regulates their proliferation and differentiation. In order for this an IL1beta cascade to begin regulating macrophage activity they must be initially activated by
cytokines from the damaged tissue site. Returning now to the argument of IL-13RA2
expression, when significant damage occurs this gene is heavily up-regulated and blocks
the release of IL-13 inhibiting macrophage activation and may be a factor in the observed
weak inflammatory response. Obviously the issues involved in tendinopathy are not
going to be solved by a single factor, but this data shows that improving our
understanding of cytokine activity and its impact on inflammatory regulation will give
further insight into the reasoning for why tendons fail to follow typical wound healing.
Another factor to consider would be intracellular gene regulation pathways of these
chemokines similar to those found from PCA. While reviewing the literature, it seemed
that the most well defined genes are those of cellular response. Studying diseases from
initial input through intracellular pathways to final cellular response will allow for a more
holistic understanding of underlying issues.
Other genes of importance to consider continued research in include ADAM12
and COL4A3. These genes encode proteins functioning in matrix anabolism and
catabolism respectively. Although these functions oppose each other, both are required
for normal wound healing in which disintegrins and MMPS like ADAM12 breakdown
damaged extracellular matrix while fibroblastic cells produce new collagenous
extracellular matrix.
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Literature has shown a significant increase in ADAM12 expression, accounting
for continuously worsening mechanical properties of the tendon as extracellular matrix is
broken down (Jelinsky et al., 2011). Expression data has shown that COL4A3 is
significantly down regulated in tendinopathy, meaning that new extracellular matrix
proteins in this domain are not being produced. This shows a possible imbalance in
extracellular matrix anabolism and catabolism, but collagen type 4 is not commonly
present in tendons making observations seemingly less significant.
4.4 Discussion of Secondary Normalization
The secondary normalization and volcano plot gave further insight into the
biomedical constraints of the original study and debates whether or not the control set
was effectively selected. From section 3.1, it is seen that healthy tissue selection was
determined based on feasibility during the disease state biopsy. But these healthy sites
were often muscular regions, which is an unintuitive control for diseased tendon
(majority subscapular, bicep and quadricep tissue).
Before considering this further, note that the original study filtered the original
set around genes of interest, specifically collagen, cytokine, MMP and TIMP transcripts.
While these expressions are biologically interesting with respect to the disease state, the
absolute value of their log-fold change was smaller than any of the muscular expressions.
From Fig 4.3 and Table 4.3, it is shown that down regulation of multiple myosin and
troponin transcripts have absolute log fold-changes from 4-6 while the original
interesting gene set lies within a 1-2 fold-change (Jelinsky et al.). From Jelinsky et al. and
others, the role of the fibrosis pathway in tendinopathy is shown to be vital in our
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understanding of cellular mechanisms at play, but such consistent down regulation of
muscular expressions leads us back to the original sample selection. Reconsidering the
original paper’s healthy sample selection, 52% of samples were from surrounding
muscular tissue not healthy tendon. This evidence strengthens the argument that the data
collected is skewed due to poor methods within collection (The Human Protein Atlas).
It was also noted that multiple transcripts for the actin alpha 2 subunit were
heavily down regulated as well. This is an interesting observation because it has been
shown that cellular adhesion and motility changes drastically in the disease state. Actin is
an intracellular filament that is involved in maintaining the structure and mechanical
response of the cell. From chapter two, tenocytes at the disease site have been shown to
lose ECM connection and form rounded cartilaginous cellular structure instead of healthy
spindle-like arrangement. However, in considering again the healthy sample selection and
muscular expression, it has been shown that act2 is expressed most heavily in muscular
tissue as they have a continuously dynamic structure. Therefore the heavy down
regulation of act2 in the disease state seems to be another artifact of poor sample
selection rather than true difference in tenocyte expression.
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Chapter 5
Conclusion & Future Implications
5.1 Conclusion
From the literature, tendinopathy seems to be marked by a combination of poorly
perfused tissue along with a lack of cellular control throughout the inflammatory and
remodeling phases of wound healing. Because of this, new generations of experimental
therapies involve implementing a cocktail of growth factors and cytokines in an effort to
control and perhaps expedite the wound healing process. As our understanding of cell
biology continues to improve, especially in the area of stem cell therapy, it seems that
these therapeutics could become effective medicines. Underlying this however is an
understanding of many different pathways at hand all with a plethora of regulators
changing based on stimuli upstream in their respective pathway. The most prominent
pathways involved seem to be extracellular matrix metabolism and chemokine pathways.
Interestingly, the chemokine pathways exist in a very dynamic system in which
cell-signaling events occur from tenocytes to macrophages as well as amongst
differentiating macrophage populations. Improvements in our understanding of cell
differentiation and function in this area will help create a more clear picture of the
underlying issues through considering each cell type as a separate but responsive system.
While in theory this seems exciting, in order to study gene expressions of each cell type
individually we must first jump major hurdles in defining and collecting separated
populations.
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From further consideration of the Jelinsky study within the renormalization step,
it was shown that initial sample collection criteria needs to be improved upon in order to
gain a more accurate understanding of the fibrosis pathway’s involvement in
tendinopathy. This can be seen from Fig 4.3 and Table 4.3 above, in which the majority
of significantly down regulated expressions are involved muscular tissue-type expression.
This does not make the current findings within the literature on the effects of the fibrosis
pathway in tendinopathy illegitimate, but it does raise concern about the original studies
significance.

5.2 Future Implications
In terms of statistical analysis moving forward, further use of the Bioconductor
package in R should be assessed so that we can view microarray data from an expression
set in plots of multiple statistical analyses quickly for preliminary observation. Also,
using the AFFY package within Bioconductor allows for comparison of results based on
normalization types. While this is not helpful information toward a specific biological
question, it may give insight on how microarray can be useful across applications and on
how to safely use this tool without being lead down faulty paths due to insignificant
observations.
Gene Set Enrichment Analysis may be a better option for high throughput data
than PCA especially on microarray data because it considers differential expression of
gene sets aligning with Affymetrix libraries. It also takes a global pathway analysis
perspective taking initial inputs as specified gene sets of interest and considers their
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expression across two biological states. This could ultimately be used to consider MMPTIMP-ADAM-COL expression to further study ECM metabolism or chemokine
inhibition and activation pathways to trace underlying cause of cellular response. An
expedited GSEA was run across all human tissue types through the Msig database and its
resulting heat map is within Appendix C. This analysis was completed for a significantly
down-regulated set from our secondary normalization. Because of this, none of the
fibrosis pathway transcripts were involved and it instead gave insight into initial sample
collection similar to Table 4.3. Future iterations of GSEA may consider a comparison of
disease state fibrosis transcripts against healthy skeletal muscle as background. This
should show that the global pathway analysis completed in the original paper is a
characteristic of differing tissue types more so than differing disease states.
Another alternative statistical approach is linear discriminant analysis. LDA is
very similar to PCA, except it looks to maximize the seperability of two categories. It
does this by defining its component similarly to PCA methods, but then check the ratio of
each categories mean to scatter. High mean difference and low scatter is the optimal
solution and allows the computer to better differentiate between disease states.
RNAseq is the new generation of tools focused on collection of genetic
information with major advantages compared to gene chip microarrays. As discussed
earlier, microarray requires an initial library to be created in order to compare new arrays
to an initially defined genome. RNAseq also has a much better signal to noise ration
because probe specificity is much better than in microarray. This is because RNAseq has
single base pair resolution via fluorescent tagging on each nucleotide within a sample and
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fluorescently activating them pair-by-pair. Because of this advantage, RNAseq can
compare a target gene to all of its isoforms and splice variants. This removes the need for
an initial library to be created and allows for the possibility of finding novel gene
expressions. This also makes RNAseq a much more sensible application for observation
of differences between healthy and diseased cells by direct comparison.
The major disadvantage of RNAseq is that it has been more expensive than
microarray in the past decade. But the cost of RNAseq is dropping as methods in both
data collection and processing continue to improve. Now that Seq technology is reaching
a more affordable cost, research using these methods will likely increase and possibly
replace microarray.
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APPENDICES
Appendix A
PCA CODE IN R
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Appendix B
Creating an Expression Set in Bioconductor
# Load Packages/Dependencies for Bioconductor
if (!"BiocManager" %in% rownames(installed.packages()))
install.packages("BiocManager")
BiocManager::install(c("affy", "limma"), dependencies=TRUE)
# AFFYMETRIX HG-U133 2 Plus annotation
BiocManager::install("hgu133plus2.db")
#AFFYMETRIX Methods for Analysis
BiocManager::install("affy")
BiocManager::install("simpleaffy")
if (!requireNamespace("BiocManager", quietly = TRUE))
install.packages("BiocManager")
BiocManager::install("GEOquery")
library(affy)
library(Biobase)
library(genefilter)
library(BiocGenerics)
library(limma)
library(GEOquery)
#Get expression data directly from GEO
gse <- getGEO("GSE26051",GSEMatrix=FALSE)
head(Meta(gse))
names(GSMList(gse))
GSMList(gse)[[1]]
# check names of the GPLs represented in case of different
platforms across samples
#names(GPLList(gse))
gse26051 <- getGEO('GSE26051',GSEMatrix=TRUE)
show(gse26051)
#check names of the GPLs represented in case of different
platforms across samples
gsmplatforms <- lapply(GSMList(gse),function(x)
{Meta(x)$platform_id})
head(gsmplatforms)
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#Splt GSE into list of GSMs for expression set
gsmlist = Filter(function(gsm)
{Meta(gsm)$platform_id=='GPL570'},GSMList(gse))
length(gsmlist)
Table(gsmlist[[1]])[1:5,]
probesets <- Table(GPLList(gse)[[1]])$ID
data.matrix <- do.call('cbind',lapply(gsmlist,function(x)
{tab <- Table(x)
mymatch <- match(probesets,tab$ID_REF)
return(tab$VALUE[mymatch])
}))
data.matrix <- apply(data.matrix,2,function(x)
{as.numeric(as.character(x))})
data.matrix <- log2(data.matrix)
data.matrix[1:5,]
# Use Biobase subpackage to convert into an expression set
for input into "affy" functions
require(Biobase)
rownames(data.matrix) <- probesets
colnames(data.matrix) <- names(gsmlist)
pdata <- data.frame(samples=names(gsmlist))
rownames(pdata) <- names(gsmlist)
pheno <- as(pdata,"AnnotatedDataFrame")
eset2 <new('ExpressionSet',exprs=data.matrix,phenoData=pheno)
eset2
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Appendix C
GSEA of Down Regulated Expressions
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Appendix D
Volcano Plotting in R
# Add packages
library(ggplot2)
library(Biobase)
library(genefilter)
library(affy)
library(BiocGenerics)
library(limma)
#Input raw GEO data -- define Gene_id as index %
micro <- read.csv("Full Set_tagged.csv",TRUE,",")
#tags <- read.csv("Affymetrix tags")
gene_tags <- micro$Gene_id
micro$Gene_id <- NULL
# Separate healthy and diseased samples for t.test
micro1 <- micro[,1:23]
micro2 <- micro[,24:46]
## Take mean intensity for H/D
micro1_mean <- apply(micro1, 1, mean)
micro2_mean <- apply(micro2, 1, mean)
#calculate fold change
foldchange <- log2(micro2_mean) - log2(micro1_mean)
hist(foldchange, xlab = "log2 Fold Change (Control vs
Test)")
# t.test with p-vals
ttestmicro <- function(df, grp1, grp2) {
x = df[grp1]
y = df[grp2]
x = as.numeric(x)
y = as.numeric(y)
results = t.test(x, y)
results$p.value
}
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rawpvalue = apply(micro, 1, ttestmicro, grp1 = c(1:23),
grp2 = c(24:43))
hist(rawpvalue)
results = cbind(foldchange, rawpvalue)
results = as.data.frame(results)
results$probesets <- rownames(results)
rownames(results) <- probesets
library(ggplot2)
##Volcano Plot w categorical coloring to determine genes of
interest
logpval <- -log(rawpvalue)
res <- results
with(res, plot(foldchange, logpval, pch=20, main="Volcano
plot", xlim=c(-3,3)))
# Add colored points: red if padj<0.05, orange of log2FC>1,
green if both)
with(subset(res, rawpvalue<.05 ), points(foldchange,
logpval, pch=20, col="red"))
with(subset(res, abs(foldchange)>1), points(foldchange,
logpval, pch=20, col="orange"))
with(subset(res, rawpvalue<.05 & abs(foldchange)>1),
points(foldchange, logpval, pch=20, col="green"))
## Filter genes upregulated in healthy state (foldchange>1,
-log10(pval)>1.3 == pval<0.05)
results_filtered = results[foldchange>1] #,
rawpvalue<0.05]]
## Filter genes upregulated in both healthy and disease
states
Healthy_upreg = dplyr::filter(results, foldchange>1.5)
Healthy_upreg = dplyr::filter(results, rawpvalue<0.05 )
## Choose -3 fold change to get smaller cluster of
observations (< -2 have +2000)
diseased_upreg = dplyr::filter(results, foldchange< -3 )
diseased_upreg = dplyr::filter(results, rawpvalue<0.05 )
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